Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hcpatocellular carcinoma (HCC) Cohort.

被引：1

作者：

Kelley, Robin Kate

Siu, Lillian L.

Van Loon, Katherine

Tolcher, Anthony W.

Razak, Albiruni R. A.

Zlyeh, Sharvina

Beeram, Muralidhar

Bedard, Philippe L.

Arcos, Rebecca

Gao, Bo

Trail, Pamela

Adriaens, Lieve

Brownstein, Carrie M.

Lowy, Israel

Papadopoulos, Kyriakos P.

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[4] START Ctr Canc Care, San Antonio, TX USA

[5] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.2540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2540

引用

页数：1

共 22 条

[1] A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Papadopoulos, Kyriakos P.
Kelley, Robin Kate
Tolcher, Anthony W.
Razak, Albiruni R. Abdul
Van Loon, Katherine
Patnaik, Amita
Bedard, Philippe L.
Alfaro, Ariceli A.
Beeram, Muralidhar
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Kostic, Ana
Trail, Pamela A.
Gao, Bo
DiCioccio, A. Thomas
Siu, Lillian L.
CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1348 - 1355
[2] A phase I first-in-human study of REGN910 (SAR307746), a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb), in patients with advanced solid tumor malignancies.
Papadopoulos, Kyriakos P.
Sahebjam, Solmaz
Kelley, Robin Katie
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Arcos, Rebecca
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[3] A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies.
Papadopoulos, K. P.
Chau, N. G.
Patnaik, A.
Adriaens, L.
Lalani, A. S.
Daly, C.
Siu, L. L.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[4] A phase Ib study of combined angiogenesis blockade with REGN910 (SAR307746), a selective monoclonal antibody (MAb) against angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid tumor malignancies.
Adriaens, Lieve
Papadopoulos, Kyriakos P.
Graham, Donna M.
Patnalk, Amita
Razak, Albiruni R. A.
Tolcher, Anthony W.
Siu, Lillian L.
Rasco, Drew Warren
Trail, Pamela
Brownstein, Carrie M.
Lowy, Israel
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies
Papadopoulos, Kyriakos P.
Graham, Donna M.
Tolcher, Anthony W.
Razak, Albiruni R. A.
Patnaik, Amita
Bedard, Philippe L.
Rasco, Drew Warren
Amaya, Alex
Moore, Kathleen N.
Konner, Jason A.
Matei, Daniela
Martin, Lainie P.
Adriaens, Lieve
Brownstein, Carrie M.
Lowy, Israel
Gao, Bo
Kostic, Ana
DiCioccio, A. Thomas
Trail, Pamela
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[6] Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors
Hidalgo, Manuel
Le Tourneau, Christophe
Massard, Christophe
Boni, Valentina
Calvo, Emiliano
Albanell, Joan
Taus, Alvaro
Sablin, Marie-Paule
Varga, Andrea
Bahleda, Ratislav
Krieter, Oliver
Markovtsova, Lada
Carlile, David
Lahr, Angelika
Nayak, Tapan
Lechner, Katharina
Koehler, Astrid
Van Uffelen, Ingrid
Martinez Garcia, Maria
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[7] BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Chu, Quincy
Leighl, Natasha B.
Surmont, Veerle
van Herpen, Carla
Sibille, Anne
Markman, Ben
Clarke, Stephen
Juergens, Rosalyn A.
Rivera, Mirelis Acosta
Andelkovic, Vladimir
Rudin, Charles M.
Snow, Stephanie
Kim, Dong-Wan
Sanatani, Michael
Lin, Hongxia
Sanghavi, Kinjal
Tannenbaum-Dvir, Sarah
Basciano, Paul
Lathers, Deanne
Urbanska, Katarzyna
Kollia, Georgia
He, Chunsheng
Dipiero, Andrew
Liu, Yu
Ready, Neal
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
[8] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTS
Friedman, Claire
Ascierto, Paolo
Davar, Diwakar
O'Hara, Mark
Shapira-Frommer, Ronnie
Dallos, Matthew
Khemka, Vivek
James, Lee
Fischer, Bruce
Demes, Shilpa
Li, Li
Kozicki, Martin
Ravindran, Palanikumar
Xu, Ke
Kollia, Georgia
Shoukry, Jacqueline
Yunan, Mona
Massey, Ashish
Gutierrez, Martin
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239
[9] The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study
Liu, S.
Zhang, J.
Chen, Z.
Zhang, Y.
Wang, J.
Chen, Y.
Chen, J.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S32
[10] Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Zonder, Jeffrey A.
Richter, Joshua
Bumma, Naresh
Brayer, Jason
Hoffman, James E.
Bensinger, William I.
Wu, Ka Lung
Xu, Linzhi
Chokshi, Dhruti
Boyapati, Anita
Sharma, Manish
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Dhodapkar, Mahdav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
BLOOD, 2021, 138

← 1 2 3 →